Lacosamide for Epileptic Seizures in Patients with Comorbidities and Unusual Presentations of Epilepsy

详细信息    查看全文

• 作者：Dr Alba Sierra-Marcos (1)
  Dr Pedro Emilio Bermejo (2)
  Dr Raquel Manso Calderón (3)
  Dr ángela María Gutiérrez-álvarez (4)
  Catalina Jiménez Corral (4)
  Daniel Sagarra Mur (4)
  
• 刊名：CNS Drugs
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：25
• 期：1-supp
• 页码：17-26
• 全文大小：427KB
• 参考文献：1. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58(8 Suppl. 5): S2- CrossRef
  2. Sander JW. The use of antiepileptic drugs -principles and practice. Epilepsia 2004; 45(Suppl. 6): 28-4 CrossRef
  3. Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 2010; 10(5): 663- CrossRef
  4. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30 (6 Suppl. 19): 49-2 CrossRef
  5. Ruggiero A, Rizzo D, Mastrangelo S, et al. Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? Pediatr Blood Cancer 2010; 54(2): 193-
  6. Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas -incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg 2010; 35: 81-11 CrossRef
  7. Bien CG, Elger CE. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 2007; 10(4): 529-8 CrossRef
  8. Graus F, Saiz A. Limbic encephalitis: an expanding concept. Neurology 2008; 70(7): 500- CrossRef
  9. Graus F, Saiz A, Lai M, et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 2008; 71(12): 930- CrossRef
  10. Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009; 50(Suppl. 12): 58-0 CrossRef
  11. Bayreuther C, Bourg V, Dellamonica J, et al. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord 2009; 11(3): 261-
  12. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67(12 Suppl. 4): S10- CrossRef
  13. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6(5): 421-0 CrossRef
  14. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008; 30(8): 1385-07 CrossRef
  15. Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996; 9(6): 424- CrossRef
  16. Margain D, Peretti-Viton P, Arnaud O, et al. Astrocytic tumours. J Neuroradiol 1991; 18(2): 141-2
  17. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav 2010; 17(4): 461- CrossRef
  18. Bernardi S, Scaldaferri N, Vanacore N, et al. Seizures in Alzheimer’s disease: a retrospective study of a cohort of outpatients. Epileptic Disord 2010; 12(1): 16-1
  19. Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009; 66(8): 992- CrossRef
  20. Ito M, Echizenya N, Nemoto D, et al. A case series of epilepsy-derived memory impairment resembling Alzheimer disease. Alzheimer Dis Assoc Disord 2009; 23(4): 406- CrossRef
  21. Larner AJ. Epileptic seizures in AD patients. Neuromolecular Med 2010; 12(1): 71- CrossRef
  22. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38(10): 1082- CrossRef
  23. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004; 56(3): 431- CrossRef
  24. Quigg M, Smithson SD, Fowler KM, et al. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology 2009; 73(3): 223- CrossRef
  25. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? Epilepsia 1993; 34(5): 827-1 CrossRef
  26. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976; 54(4): 321-7 CrossRef
  27. Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61(6 Suppl. 2): S2-5 CrossRef
  28. Krishnamurthy KB, Schomer DL. Weekly fluctuation and adjustment of antiepileptic drugs to treat catamenial epilepsy [abstract]. Epilepsia 1998; 39(Suppl. 6): 179
  29. Gilad R, Sadeh M, Rapoport A, et al. Lamotrigine and catamenial epilepsy. Seizure 2008; 17(6): 531- CrossRef
  30. Knake S, Hamer HM, Rosenow F. Status epilepticus: a critical review. Epilepsy Behav 2009; 15(1): 10- CrossRef
  31. Manno EM. New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78(4): 508-8 CrossRef
  32. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006; 8(3): 651- CrossRef
  33. Chung S, Sperling MR, Biton V, et al. Lacosamide as ad-junctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51(6): 958-7 CrossRef
  34. Kelemen A, Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 2010; 6: 465-1 CrossRef
  35. Tilz C, Resch R, Hofer T, et al. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010; 51(2): 316-7 CrossRef
  36. Turpin-Fenoll L, Millan-Pascual J, Navarro-Munoz S, et al. [The use of oral lacosamide in a patient with refractory partial epileptic status]. Rev Neurol 2010; 50(10): 603-
  37. Wehner T, Bauer S, Hamer HM, et al. Six months of post-marketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16(3): 423- CrossRef
  
• 作者单位：Dr Alba Sierra-Marcos (1)
  Dr Pedro Emilio Bermejo (2)
  Dr Raquel Manso Calderón (3)
  Dr ángela María Gutiérrez-álvarez (4)
  Catalina Jiménez Corral (4)
  Daniel Sagarra Mur (4)
  
  1. Hospital Clínic de Barcelona, Calle Villarroel 170, 08036, Barcelona, Spain
  2. Bermejo Hospital Universitario Puerta de Hierro, Manuel de Falla 1, 28222, Majadahonda, Madrid, Spain
  3. Hospital Nuestra Se?ora de Sonsoles, Avenida Juan Carlos I, S/N, 05004, ávila, Spain
  4. Hospital de Santa Barbara, P de Santa Barbara, S/N, Soria, 42005, Spain
  
• ISSN：1179-1934

文摘

Numerous patients who are prescribed antiepileptic drugs (AEDs) for epileptic seizures are already receiving other agents for the treatment of co-morbid conditions, which frequently occur alongside epilepsy. This raises additional clinical considerations and makes the use of AEDs with good safety profiles and fewer drug-drug interactions attractive. Second and third-generation anticonvulsant drugs are associated with fewer pharmacological interactions and improved tolerability compared with first-generation drugs. Furthermore, second and third-generation anticonvulsant drugs are associated with linear pharmacokinetic profiles and differing mechanisms of action, making them ideal for pluripathological and polymedicated patients. In this report, we highlight the efficacy of one such agent, lacosamide, in five patients with co-morbidities and unusual presentations of epilepsy, including a patient with paraneoplastic encephalitis caused by microcytic lung carcinoma, one with a brain tumour and one with Alzheimer’s disease, as well as a case of catamenial epilepsy and one of refractory convulsive status epilepticus. In all patients, lacosamide was associated with a substantial reduction in seizure frequency and effective control of seizure episodes. Treatment was generally well tolerated in all patients, indicating that lacosamide is an effective treatment option for a variety of patients with epileptic seizures.